UGN-102 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of commercial shipping and naval activity in the Strait of Hormuz, as Iran reopens the key oil transit route while uncertainty over the United States naval blockade continues.

Strait of Hormuz reopens on paper, yet ships turn back as Iran and US clash over blockade terms

TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record

Representative image of a large-scale copper mining operation in Chile, reflecting investor focus on Antofagasta PLC shares, Q1 2026 production stability, and the Centinela Second Concentrator growth story.

Antofagasta (LSE: ANTO) surges 5% as Q1 output beats consensus and Centinela build holds schedule

Shubman Gill’s 86 steers Gujarat Titans past Kolkata Knight Riders in IPL 2026

Breakthrough for recurrent bladder cancer UroGen’s UGN-102 achieves 80.6% 18-month complete response in phase 3 trial

Read More

Pharma Industry News

Breakthrough for recurrent bladder cancer: UroGen’s UGN-102 achieves 80.6% 18-month complete response in phase 3 trial

Discover how UroGen Pharma’s UGN-102 could transform bladder cancer treatment with durable results; find out what the Phase 3 ENVISION trial reveals!

byPallavi Madhiraju

April 27, 2025

web analytics